What is the duration of action of Adderall (amphetamine and dextroamphetamine) extended release?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 18, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Duration of Action of Adderall Extended Release

Adderall XR (extended-release) provides approximately 12 hours of therapeutic coverage with a single daily dose. 1, 2

Pharmacokinetic Profile

The extended-release formulation uses a dual-bead delivery system that releases medication in two phases: immediate-release beads deliver the first half of the dose upon ingestion, while delayed-release beads begin releasing the second half approximately 4 hours later. 1

Onset and Peak Effects

  • Onset of action occurs within 1.5 hours after administration, providing rapid symptom control comparable to immediate-release formulations. 1
  • Time to maximum concentration (Tmax) is delayed by approximately 3 hours compared to immediate-release Adderall, with peak plasma levels occurring around 8 hours after dosing. 3, 4
  • The average plasma half-life is approximately 12 hours for both immediate-release and extended-release formulations. 3

Duration Considerations

  • The 12-hour duration of action allows for once-daily morning dosing, eliminating the need for midday administration during school or work hours. 1, 2
  • Morning administration is essential to prevent sleep disturbances, as the 12-hour duration could interfere with nighttime sleep if taken later in the day. 5

Clinical Context

The bioavailability of Adderall XR 20 mg is comparable to immediate-release Adderall 10 mg given twice daily, maintaining the same 3:1 ratio of dextroamphetamine to levoamphetamine. 1

Important Caveats

  • Substantial intersubject variability exists in pharmacokinetic parameters (coefficients of variation 28-56%), necessitating individual dose titration rather than relying on weight-based dosing. 4
  • Food intake does not significantly affect the rate or extent of absorption with the extended-release formulation. 3
  • The extended-release formulation provides more consistent symptom control throughout the day compared to the immediate-release version, which typically lasts only 3-4 hours per dose. 6

References

Research

Adderall XR: long acting stimulant for single daily dosing.

Expert review of neurotherapeutics, 2004

Research

Pharmacokinetics of SLI381 (ADDERALL XR), an extended-release formulation of Adderall.

Journal of the American Academy of Child and Adolescent Psychiatry, 2003

Guideline

Onset of Action and Pharmacokinetics of Generic Adderall XR

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.